doxycycline and eye surface repair

Written by on October 17, 2005 in doxycycline, Ocular Rosacea with 1 Comment

Doxycycline is a broad spectrum antibiotic that chelates metal ions and is frequently used as part of treatment of ocular surface diseases. Its therapeutic value has been attributed to an ability to inhibit matrix metalloproteinase activity and both matrix metalloproteinase and interleukin-1 synthesis. Smith and Cook studied corneal epithelial cell and keratocyte cultures and in this study they demonstrated that the minimum concentration of doxycycline required to inhibit the activities of corneal matrix metalloproteinase is similar to that required to inhibit these enzymes in other tissues. If this concentration is achievable in the tears of patients treated systemically for ocular surface disorders in addition to inhibiting matrix metalloproteinases that have been pathologically activated doxycycline may kill migratory keratocytes or fibroblasts responsible for the formation of scar tissue as well as promote complete coverage of the ocular surface with epithelial basal cells.

From BJO At A GlanceDOXYCYCLINE, DOES IT REPAIR OCULAR SURFACE?


Doxycycline—a role in ocular surface repairBritish Journal of Ophthalmology, 2004;88:619-625Keywords: interleukin-1; corneal epithelial cells; corneal keratocytes; doxycycline; matrix metalloproteinases

Background/aims: Doxycycline is a broad spectrum antibiotic that chelates metal ions and is frequently used as part of the treatment of ocular surface diseases. Its therapeutic value has been ascribed to an ability to inhibit matrix metalloproteinase (MMP) activity and both MMP and IL-1 synthesis. The aim of this study was to evaluate the role of doxycycline as an inhibitor of corneal MMPs and assess its contribution to ocular surface repair mechanisms.

Methods: Corneal epithelial cell and keratocyte cultures were grown to confluence and incubated with IL-1, LPS, doxycycline, or doxycycline and LPS in serum free medium for 4 days. The cells were either harvested and assayed for caspase-3 activity or stained with either AE5 or antivimentin antibodies. Media samples were concentrated and assayed for MMP activity by zymography or using a fluorigenic substrate. ELISA was used to quantify IL-1, MMPs -1,-2,-3,-9, and TIMPs -1 and -2.

Results: IL-1 and LPS had no effect on MMP/TIMP production by cultured corneal epithelial cells and keratocytes. Corneal MMP-2 inhibition by doxycycline was partially [Ca2+] dependent but irreversible. At the minimum inhibitory concentration, 100 µm, doxycycline had no apparent effect on MMP and TIMP production, but ultimately caused the death of keratocytes and some of the epithelial cells that detached from their basement membrane. Caspase-3 activity was not detected in dead or dying keratocytes. The mechanism of cell death in cultured corneal epithelial cells was not caspase-3 related apoptosis as the activity of this enzyme, normally detectable, was lost. The epithelial cells that survived doxycycline treatment did not bind antivimentin antibody and compared with controls, reacted less with the AE5 antibody. They were probably transient amplifying cells.

Conclusions: Doxycycline irreversibly inhibits corneal MMP-2 activity by chelating the metal ions that are catalytically and structurally essential. Corneal MMP/TIMP production in vitro is not modulated by IL-1, LPS, or doxycycline. The therapeutic value of doxycycline may depend upon its effective concentration at the ocular surface and probably relates to its chelating properties.

Related Articles

Read more about: doxycycline, Ocular Rosacea

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

1 Reader Comment

  1. Serge says:

    I’m 40, male, and had two corneal tears when I was age 38. Both corneal tears occurred in the early morning upon waking when my eyelid stuck to and tearing the cornea of my right eye.

    I had been diagnosed earlier with rosacea at age 37. After the second corneal tear incident, I asked my dermatologist, with my opthamologist’s okay, to put me on 100mg of doxcycline a day.

    After starting the dox regimen, the doxcycline put a stop to the corneal erosion with no further corneal tears. Furthermore, symptoms associated with rosacea, including the “eye grittiness” sensation, have ceased.

    No side effects except for sun sensitivity. I get sun burned very easily.

    I will stay on dox for the rest of my life. I believe that as an MMP inhibitor and anti-inflammatory, the doxcycline should also help inhibit the onset of wet macular degeneration and arthritis in my later years. So, I feel that the corneal tears were a blessing in disguise.

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.